(Q46836109)

25 December 2017

title

Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement (English)

1 reference

25 December 2017

author name string

Luciana Diniz Carneiro Spina

1

1 reference

25 December 2017

Débora Vieira Soares

2

1 reference

25 December 2017

Rosane Resende de Lima Oliveira Brasil

3

1 reference

25 December 2017

Priscila Marise Lobo

4

1 reference

25 December 2017

Flávia Lúcia Conceição

5

1 reference

25 December 2017

Mário Vaisman

6

1 reference

25 December 2017

publication date

1 January 2004

1 reference

25 December 2017

published in

Pituitary

1 reference

25 December 2017

volume

7

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

123-129

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1007/s11102-005-5065-6

exact match

0 references

cites work

Beneficial effects of growth hormone treatment in GH-deficient adults

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Effect of growth hormone on carbohydrate and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

A prospective analysis of the HOMA model. The Mexico City Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Diagnosing insulin resistance in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

REPRODUCIBILITY OF THE ORAL GLUCOSE TOLERANCE TEST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Reproducibility of oral glucose tolerance data in normal and mildly diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Absence of effects of long-term growth hormone replacement therapy on insulin sensitivity in adults with growth hormone deficiency of childhood-onset (GHDA-CO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

A low individualized GH dose in young patients with childhood onset GH deficiency normalized serum IGF-I without significant deterioration in glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Can growth hormone therapy cause diabetes? KIMS Strategic Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-005-5065-6

Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience

21 January 2018

1 reference

12 December 2020

Studies on the pathogenesis of diabetes in acromegaly

1 reference

12 December 2020

Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas

1 reference

12 December 2020

Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults

1 reference

12 December 2020

Effects of 7 years of growth hormone replacement therapy in hypopituitary adults.

1 reference

12 December 2020

The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition

1 reference

12 December 2020

Effect of 12 months of recombinant human growth hormone replacement therapy on insulin sensitivity in GH-deficient adults as determined by different methods.

1 reference

12 December 2020

The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.

1 reference

12 December 2020

Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults

1 reference

12 December 2020

The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients

1 reference

12 December 2020

Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease

1 reference

12 December 2020

The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults

1 reference

12 December 2020

The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance.

1 reference

12 December 2020

Treatment of adults with growth hormone (GH) deficiency with recombinant human GH

1 reference

12 December 2020

The effect of growth hormone on glucose metabolism and insulin secretion in man

1 reference

12 December 2020

The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.

1 reference

12 December 2020

Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.

1 reference

12 December 2020

10.1007/S11102-005-5065-6

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017